Proud to share our work on mortality outcomes in patients who received ICI and who were treated with dupilumab for cirAE management.
Thankful for the support of my mentors @EugeneSemenovMD, Dr. Nicole LeBoeuf, and @GHWANPhD
New #JITC article: Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events https://t.co/syFotECuoZ @CaImmunoprevent@EugeneSemenovMD
Online First:
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
#immunotherapy#ICIs#irAEs
https://t.co/ZI0uoTI0uI
Super excited to share our @TheLancetOncol study identifying improved survival among patient clusters dominated by cutaneous and endocrine immunotherapy toxicities, which was also highlighted by @ASCO (https://t.co/Z17ckRcRXw). Thanks to my mentors @EugeneSemenovMD and @GHWANPhD.
Extremely proud of the team, especially @GHWANPhD, @khattabsaray, and @wxchen953 for our @TheLancetOncol study on multi-organ toxicities from checkpoint blockade, providing a roadmap for prognosticating outcomes via the lens of immunotherapy toxicities: https://t.co/Vy7pHIftgo
Very excited to share our Delphi consensus guidelines to diagnosing dermatologic immunotherapy toxicites. Incredible team effort from more than 30 experts, including @DrStevenTChen@kreynoldsMD, @DrJNaidoo, and Nicole LeBoeuf.
Excited to share our @JAMADerm viewpoint https://t.co/gr3NepEeWB examining immunotherapy in localized melanoma. Big congrats to @HannahRashdan in my lab for leading the piece, which was also a hot topic @ the most recent @MelanomaReAlli meeting! Thx to @AdeAdamson for his collab.